Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10327460 | 0.85 | CDK8 (0.49) | ADORA3CDK8ROCK1DYRK1ACHEK1 | |
| SCHEMBL12604003 | 0.85 | ADORA3 (0.39) | ADORA3CDK8ROCK1DYRK1ACHEK1 | |
| SCHEMBL9609560 | 0.77 | SSTR4 (0.48) | ADORA3DYRK1ASSTR4KDM4EKMT2A | |
| SCHEMBL15233358 | 0.74 | ADORA3 (0.52) | ADORA3CDK8ROCK1DYRK1ACHEK1 | |
| SCHEMBL21672752 | 0.73 | GABRA1 (0.31) | — | |
| SCHEMBL12395090 | 0.72 | EGLN2 (0.38) | DYRK1AKDM4EKMT2AATMMEN1 | |
| SCHEMBL23232278 | 0.70 | CDK8 (0.46) | ADORA3CDK8ROCK1DYRK1ACHEK1 | |
| SCHEMBL13431462 | 0.69 | NR3C1 (0.31) | CDK8ROCK1DYRK1ACHEK1MAP4K4 | |
| SCHEMBL18237968 | 0.69 | ADORA3 (0.52) | ADORA3CDK8ROCK1DYRK1ACHEK1 | |
| SCHEMBL10281041 | 0.69 | ADORA3 (0.47) | ADORA3CDK8ROCK1DYRK1ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8212041-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ADORA3 3524/4885CDK8 1344/4885ROCK1 2186/4885 |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | ADORA3 3524/4885CDK8 1344/4885ROCK1 2186/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ADORA3 3524/4885CDK8 1344/4885ROCK1 2186/4885 |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | HGF, HGFAC, MET | ADORA3 3918/4885CDK8 231/4885ROCK1 708/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ADORA3 3524/4885CDK8 1344/4885ROCK1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.